Scorpius Holdings, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $6.2M | $7.0M | $370,176 | $2.1M | $2.9M | $3.0M |
| Operating income | −$33.6M | −$42.0M | −$40.2M | −$35.4M | −$26.1M | −$20.7M |
| Net income | −$32.8M | −$45.2M | −$43.4M | −$35.1M | −$26.0M | −$20.0M |
| Total assets | $39.2M | $51.0M | $104.4M | $121.0M | $124.2M | $26.0M |
| Total liabilities | $37.5M | $22.7M | $32.0M | $8.9M | $8.7M | $12.8M |
| Equity | $6.3M | $31.4M | $73.9M | $113.1M | $116.2M | $13.6M |
| EPS (diluted) | $-13.04 | $-347.50 | $-1.70 | $-1.41 | $-1.63 | — |
| Shares out. | 36.0M | 26.0M | 25.6M | 25.4M | 79.4M | 33.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −538.2%
- Net margin
- −525.5%
- Return on equity
- −520.8%
- Return on assets
- −83.7%
- Return on capital (ROCE)
- −225.7%
- Liabilities / assets
- 95.7%
- Debt / equity
- 5.95×
- Book value / share
- $0.17
- Revenue growth (YoY)
- −10.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -33.00distress
- Accruals / assets
- −17.4%clean
- Beneish M-Score
- -4.15normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 18, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Qmissed a reporting deadline ↗May 15, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
- NT 10-Qmissed a reporting deadline ↗May 16, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- 3i, LpPassive (13G)Feb 5, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 24, 2026
- Director / officer changeApr 8, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleMar 19, 2026
- Completed an acquisition or disposition · Debt acceleration / triggering eventJan 29, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleJan 13, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleDec 3, 2025
- Entered a material agreement · New financial obligation · Unregistered equity saleDec 2, 2025
- Entered a material agreement · New financial obligation · Unregistered equity saleNov 25, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KApr 24, 2026
- 8-KFORM 8-KApr 8, 2026
- 8-KFORM 8-KMar 19, 2026
- 8-K/AFORM 8-K/AMar 10, 2026
- 10-QFeb 17, 2026
- SCHEDULE 13G/AFeb 5, 2026
- 8-KFORM 8-KJan 29, 2026
- 8-KFORM 8-KJan 13, 2026
- 10-QJan 12, 2026
- 8-KFORM 8-KDec 3, 2025
- 8-KFORM 8-KDec 2, 2025
- 8-KFORM 8-KNov 25, 2025
- NT 10-QNOTIFICATION OF LATE FILINGNov 18, 2025
- 8-KFORM 8-KNov 17, 2025
- SCHEDULE 13G/ANov 12, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.